CHARLOTTESVILLE, VA – January 29, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million. The [...]
CHARLOTTESVILLE, VA – February 6, 2009 – Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs that enhance oxygen diffusion, today announced the completion of a $2.9 million private placement. The proceeds will support the company’s overall growth and clinical programs for its lead drug compound, trans sodium crocetinate (TSC). In addition, David [...]
CHARLOTTESVILLE, VA – September 28, 2007 – Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced the results of a Phase I safety trial of its lead drug candidate, trans sodium crocetinate (TSC). In addition, the company announced the completion of [...]
CHARLOTTESVILLE, VA – February 2, 2007 – Diffusion Pharmaceuticals LLC, a drug discovery and development company pioneering a revolutionary approach to treat life-threatening diseases, today announced that it has received a $0.5 million grant (N00014-07-C-0424) from the Office of Naval Research (ONR). The funds will be used to support the transition of the company’s lead [...]
Human Testing Expected to Begin in Early 2007 CHARLOTTESVILLE, VA — October 17, 2006 — Diffusion Pharmaceuticals LLC, a drug discovery and development company pioneering a revolutionary mechanism of action to treat life-threatening diseases, today announced that it has completed all animal toxicology studies required by the U.S. Food and Drug Administration (FDA) to file [...]
